TY - JOUR
T1 - Truncated Forms of the Insulin-like Growth Factor II (IGF-II)/ Mannose 6-Phosphate Receptor Encompassing the IGF-II Binding Site
T2 - Characterization of a Point Mutation That Abolishes IGF-II Binding
AU - Garmroudi, Farideh
AU - Devi, Gayathri
AU - Slentz, Dorothy H.
AU - Schaffer, Beverly S.
AU - MacDonald, Richard G.
PY - 1996
Y1 - 1996
N2 - Complete understanding of the functional significance of insulin-like growth factor II (IGF-II) binding by the IGF-II/mannose-6-phosphate (Man-6-P) receptor requires mapping and ultimately mutational analysis of the receptor's IGF-II binding domain. Recent advances have localized the IGF-II binding site to extracytoplasmic repeats 10-11. To improve resolution of the binding site map, a nested set of epitope-tagged, truncated forms of the human IGF-II/Man-6-P receptor were transiently expressed in COS-7 cells. The IGF-II binding properties of truncated receptors immunoprecipitated from cell lysates and conditioned media were determined by affinity cross-linking. From the largest truncated receptor, encompassing extracytoplasmic repeats 8-11 (Mr 68 K), through the smallest, comprised primarily of repeat 11 (Mr 23 K), all were able to bind and cross-link to IGF-II. As a group, the truncated receptors had similar affinities for IGF-II, but with relative binding affinities 5-to 10-fold lower than those of full-length receptors. A point mutation substituting threonine for isoleucine at residue 1572, located in the NH2-terminal half of repeat 11, completely abolished IGF-II binding. We conclude that repeat 11 of the IGF-II/Man-6-P receptor's extracytoplasmic domain contains the minimal elements required for binding and cross-linking to IGF-II, and that Me1572 and other residues within the NH2-terminal half of repeat 11 are particularly important for IGF-II interaction.
AB - Complete understanding of the functional significance of insulin-like growth factor II (IGF-II) binding by the IGF-II/mannose-6-phosphate (Man-6-P) receptor requires mapping and ultimately mutational analysis of the receptor's IGF-II binding domain. Recent advances have localized the IGF-II binding site to extracytoplasmic repeats 10-11. To improve resolution of the binding site map, a nested set of epitope-tagged, truncated forms of the human IGF-II/Man-6-P receptor were transiently expressed in COS-7 cells. The IGF-II binding properties of truncated receptors immunoprecipitated from cell lysates and conditioned media were determined by affinity cross-linking. From the largest truncated receptor, encompassing extracytoplasmic repeats 8-11 (Mr 68 K), through the smallest, comprised primarily of repeat 11 (Mr 23 K), all were able to bind and cross-link to IGF-II. As a group, the truncated receptors had similar affinities for IGF-II, but with relative binding affinities 5-to 10-fold lower than those of full-length receptors. A point mutation substituting threonine for isoleucine at residue 1572, located in the NH2-terminal half of repeat 11, completely abolished IGF-II binding. We conclude that repeat 11 of the IGF-II/Man-6-P receptor's extracytoplasmic domain contains the minimal elements required for binding and cross-linking to IGF-II, and that Me1572 and other residues within the NH2-terminal half of repeat 11 are particularly important for IGF-II interaction.
UR - http://www.scopus.com/inward/record.url?scp=0029969904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029969904&partnerID=8YFLogxK
U2 - 10.1210/mend.10.6.8776724
DO - 10.1210/mend.10.6.8776724
M3 - Article
C2 - 8776724
AN - SCOPUS:0029969904
SN - 0888-8809
VL - 10
SP - 642
EP - 651
JO - Molecular Endocrinology
JF - Molecular Endocrinology
IS - 6
ER -